B. Yu

Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.

Zhaoqian Liu, Xiaoping Chen, Honghao Zhou, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

Wei Zhang, An Wang, Honghao Zhou, 2005, European Journal of Clinical Pharmacology.

CYP2C9 allele variants in Chinese hypertension patients and healthy controls.

Wei Zhang, An Wang, Honghao Zhou, 2004, Clinica chimica acta; international journal of clinical chemistry.

beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension.

Zhaoqian Liu, Honghao Zhou, Qing Li, 2006, Clinical pharmacology and therapeutics.

Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide.

Wei Zhang, Zhaoqian Liu, Honghao Zhou, 2006, British journal of clinical pharmacology.

β1‐Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension

Zhaoqian Liu, Honghao Zhou, Qing Li, 2006 .

T102C genetic polymorphism of the 5‐HT2A receptor in Chinese hypertensive patients and healthy controls

Wei Zhang, An Wang, Honghao Zhou, 2004, Clinical and experimental pharmacology & physiology.

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.

Ya-li Liu, Wei Zhang, Zhaoqian Liu, 2006, Clinica chimica acta; international journal of clinical chemistry.

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.

Hong-Hao Zhou, Dong Guo, Bi-Lian Chen, 2009, Clinica chimica acta; international journal of clinical chemistry.

Gender specific association of CYP2C9*3 with hyperlipidaemia in Chinese.

R. Zhu, An Wang, Honghao Zhou, 2005, British journal of clinical pharmacology.